参附脱毒胶囊Ⅱ期临床110例双盲评估研究  

A DOUBLE-BLIND CLINICAL TRIAL OF SHENGFUTUODU CAPSULE IN THE TREATMENT OF HEROIN WITHDRAWAL SYMPTOMS

作　　者：张锐敏[1] 李吉祥[1] 孙新会[1] 郑玲[1] 杨丽萍[1] 张杰[1] 李建华[1] 马克坚[1] 袁小波[1] 万文鹏[1] 

机构地区：[1]云南省药物依赖防治研究所,昆明650228

出　　处：《中国药物依赖性杂志》2002年第3期197-201,232,共6页Chinese Journal of Drug Dependence

摘　　要：目的··:评价参附脱毒胶囊用于阿片类依赖者脱毒治疗的疗效及不良反应。方法··:110例随机双盲对照试验设计 ,对照药为盐酸可乐定 ,其中参附脱毒胶囊组80例 ,可乐定组30例。结果··:参附脱毒胶囊控制戒断症状的作用与可乐定相同 (P>0.05) ,控制典型戒断症状 (如骨肌肉痛 )优于可乐定 (P<0.05)。结论··:参附脱毒胶囊用于阿片类依赖的脱毒治疗疗效肯定 ,安全可靠 ,无严重不良反应。Objective: To evaluate the effect and safety of Shenfutuodu capsule, a traditional Chinese medicine, on alleviating opiate withdrawal symptoms in heroin addicts. Methods: A randomized, double-blind trial was carried out in 110 heroin addicts. They had been treated for 10 days. Results: In Shenfutudu group, the alleviation of withdrawal symptoms was similar to that in Clonidine group, and the effect of relieving pain was better than clonidine. Conclusion: Shenfutudu capsule is effective in the treatment of opiate withdrawal symptoms without serious side effects.

关 键 词：参附脱毒胶囊 可乐定 海洛因依赖 戒断症状 不良反应 临床研究 脱毒治疗 

分 类 号：R595.5[医药卫生—内科学] R964[医药卫生—临床医学]